Physicians Warn of Medical Risks In Trans Youth Study Allegedly Funded By Nike

Nike’s latest move in the identity politics arena isn’t a flashy ad campaign — it’s reportedly a quiet, five-year, corporate-backed study examining how puberty blockers and hormone therapy affect athletic performance in transgender-identifying kids. The goal? To see if medically transitioning boys early enough could close the performance gap between males and females in sports.

But is it ethical — or even safe — to alter children’s development to achieve parity in sports?

Two leading physicians, Dr. Marc Siegel and Dr. Nicole Saphier, say no. While both support compassion for gender-dysphoric youth, they’re sounding the alarm about medical risks, ethical red flags and ideological bias driving these interventions.

Dr. Nicole Saphier and Dr. Marc Siegel weighed in on the implications of a Nike-funded study on transgender youth.

(Getty Images)

The doctors also explained that athletic advantages for males likely wouldn't be erased by hormone therapy, no matter how early in life the treatments are administered. 

Dr. Siegel pointed out that males have more testosterone than females even in utero — long before puberty begins — affecting development in ways hormone suppression may not reverse.

"I would still be concerned about a competitive advantage in people that are born male, even if they transition over to female — because of skeletal type, because of body type," Siegel said in an exclusive interview with OutKick. "I would be very expectant that a competitive advantage would be retained."

As a physician and a mother, Dr. Saphier said she feels "deeply concerned" by reports that Nike is helping to fund a study on adolescent children using hormone blockers.

"The potential physical and mental health risks of these